Uric acid administration in patients with acute stroke: A novel approach to neuroprotection

Expert Review of Neurotherapeutics

Volumn 8, Issue 2, 2008, Pages 259-270

  Amaro, Sergio ^b   Planas, Anna M ^c   Chamorro, Ángel ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Cerebrovascular disorder; Clinical trials; Neuroprotection; Oxidative stress; Stroke

Indexed keywords

ASCORBIC ACID; PLACEBO; URIC ACID;

ABSENCE OF SIDE EFFECTS; ACUTE DISEASE; ANTIOXIDANT ACTIVITY; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; HISTOPATHOLOGY; HUMAN; HYPERTENSION; MIDDLE CEREBRAL ARTERY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; STROKE;

ANIMALS; HUMANS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; STROKE; URIC ACID;

EID: 39549086157     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.2.259     Document Type: Review

References (102)

1. Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J. Mol. Evol. 34(1), 78-84 (1992).
2. Becker BF. Towards the physiological function of uric acid. Free Radic. Biol. Med. 14(6), 615-631 (1993).
3. Garcia Puig J, Mateos FA. Clinical and biochemical aspects of uric acid overproduction. Pharm. World Sci. 16(2), 40-54 (1994).
4. Nyyssönen K, Porkkala-Sarataho E, Kaikkonen J, Salonen JT. Ascorbate and urate are the strongest determinants of plasma antioxidative capacity and serum lipid resistance to oxidation in Finnish men. Atherosclerosis 130(1-2), 223-233 (1997).
5. Watanabe S, Kang DH, Feng L et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40(3), 355-360 (2002).
6. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc. Natl Acad. Sci. USA 78, 6858-6862 (1981). •• Excellent paper which provides potential reasons to explain the persistence of higher levels of uric acid (UA) in humans in respect to other species based mainly in its antioxidant properties.
7. Bleyer AJ, Hart TC. Genetic factors associated with gout and hyperuricemia. Adv. Chronic Kidney Dis. 13(2), 124-130 (2006).
8. Hediger MA, Johnson RJ, Miyazaki H, Endou H. Molecular physiology of urate transport. Physiology 20, 125-133 (2005).
9. Doehner W, Schoene N, Rauchhaus M et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105(22), 2619-2624 (2002).
10. Volk KJ, Lee MS, Yost RA, Brajter-Toth A. Electrochemistry/thermospray/ tandem mass spectrometry in the study of biooxidation of purines. Anal. Chem. 60(7), 720-722 (1988).
11. Leal-Pinto E, Cohen BE, Abramson RG. Functional analysis and molecular modeling of a cloned urate transporter/channel. J. Membr. Biol. 169(1), 13-27 (1999).
12. Enomoto A, Kimura H, Chairoungdua A et al. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature 417(6887), 447-452 (2002).
13. Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J. Pharmacol. Exp. Ther. 280(2), 839-845 (1997).
14. Johnson RJ, Titte S, Cade JR, Rideout BA Oliver WJ. Uric acid, evolution, and primitive cultures. Semin. Nephrol. 25(1), 3-8 (2005).
15. Dröge W. Free radicals in the physiological control of cell function. Physiol. Rev. 82(1), 47-95 (2002).
16. Love S. Oxidative stress in brain ischemia. Brain Pathol. 9(1), 119-131 (1999).
17. Fabian RH, Kent TA. Superoxide anion production during reperfusion is reduced by an antineutrophil antibody after prolonged cerebral ischemia. Free Radic. Biol. Med. 26(3-4), 355-361 (1999).
18. Uemura Y, Miller JM, Matson WR, Beal MF. Neurochemical analysis of focal ischemia in rats. Stroke 22(12), 1548-1553 (1991).
19. Schneider A, Martin-Villalba A, Weih F, Vogel J, Wirth T, Schwaninger M. NF-κB is activated and promotes cell death in focal cerebral ischemia. Nat. Med. 5(5), 554-559 (1999).
20. Frijns CJ, Kappelle LJ. Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke 33(8), 2115-2122 (2002).
21. Cherubini, Polidori MC, Bregnocchi M et al. Antioxidant profile and early outcome in stroke patients. Stroke 31(10), 2295-2300 (2000).
22. Spranger M, Krempien S, Schwab S, Donnenberg S, Hacke W. Superoxide dismutase activity in serum of patients with acute cerebral ischemic injury: correlation with clinical course and infarct size. Stroke 28(12), 2425-2428 (1997).
23. Leinonen JS, Ahonen JP, Loennrot K et al. Plasma antioxidant capacity is associated with high lesion volume and neurological impairment in stroke. Stroke 31(9), 33-39 (2000).
24. Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc. Dis. 15(3), 222-229 (2003).
25. Lees KR, Zivin JA, Ashwood T et al. Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N. Engl. J. Med. 354, 588-600 (2006).
26. Shuaib A, Lees KR, Lyden P et al. NXY-059 for the treatment of acute ischemic stroke. SAINT II Trial Investigators. N. Engl J. Med. 357(6), 562-571 (2007).
27. Tirilazad International Steering Committee. Tirilazad mesylate in acute ischemic stroke: a systematic review. Stroke 31(9), 2257-2265 (2000).
28. Ly JV, Zavala JA, Donnan GA. Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke. Expert Opin. Pharmacother. 7(12), 1571-1581 (2006).
29. Zweier JL, Kuppusamy P, Lutty GA. Measurement of endothelial cell free radical generation: evidence for a central mechanism of free radical injury in postischemic tissues. Proc. Natl Acad. Sci. USA 85(11), 4046-4050 (1998).
30. Ashraf M, Samra ZQ. Subcellular distribution of xanthine oxidase during cardiac ischemia and reperfusion: an immunocytochemical study. J. Submicrosc. Cytol. Pathol. 25(2), 193-201 (1993).
31. Tayag EC, Nair SN, Wahhab S, Katsetos CD, Lighthall JW, Lehmann JC. Cerebral uric acid increases following experimental traumatic brain injury in rat. Brain Res. 733(2), 287-291 (1996).
32. Friedl HP, Smith DJ, Till GO, Thomson PD, Louis DS, Ward PA. Ischemia-reperfusion in humans. Appearance of xanthine oxidase activity. Am. J. Pathol. 136(3), 491-495 (1990).
33. Huizer T, de Jong JW, Nelson JA et al. Urate production by human heart. J. Mol. Cell Cardiol. 21(7), 691-695 (1989).
34. Lazzarino G, Raatikainen P, Nuutinen M et al. Myocardial release of malondialdehyde and purine compounds during coronary bypass surgery. Circulation 90(1), 291-297 (1994).
35. Leyva F, Anker S, Swan JW et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur. Heart J. 18(5), 858-865 (1997).
36. Akdemir H, Aik Z, Paaoqlu H, Karaküçük I, Oktem IS, Koç RK. The effect of allopurinol on focal cerebral ischaemia: an experimental study in rabbits. Neurosurg. Rev. 24(2-3), 131-135 (2001).
37. Montor SG, Thoolen MJ, Mackin WM, Timmermans PB. Effect of azapropazone and allopurinol on myocardial infarct size in rats. Eur. J. Pharmacol. 140(2), 203-207 (1987).
38. Bolli R. Oxygen-derived free radicals and postischemic myocardial dysfunction ('stunned myocardium'). J. Am. Coll. Cardiol. 12(1), 239-249 (1988).
39. Davies KJ, Sevanian A, Muakkassah-Kelly SF, Hochstein P. Uric acid-iron ion complexes: a new aspect of the anti-oxidant functions of uric acid. Biochem. J. 235(3), 747-754 (1986).
40. Squadrito GL, Cueto R, Splenser AE et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch. Biochem. Biophys. 376(2), 333-337 (2000).
41. Gürsoy-Ozdemir Y, Can A, Dalkara T. Reperfusion-induced oxidative/nitrative injury to neurovascular unit after focal cerebral ischemia. Stroke 35(6), 1449-1453 (2004). • Good experimental paper linking oxidative and nitrative stress with reperfusion injury and BBB damage.
42. Demicheli V, Quijano C, Alvarez B, Radi R. Inactivation and nitration of human superoxide dismutase (SOD) by fluxes of nitric oxide and superoxide. Free Radic. Biol. Med. 42(9), 1359-1368 (2007).
43. Nie H, Wu JL, Zhang M, Xu J, Zou MH. Endothelial nitric oxide synthase-dependent tyrosine nitration of prostacyclin synthase in diabetes in vivo. Diabetes 55(11), 3133-3141 (2006).
44. Vadseth C, Souza JM, Thomson L et al. Pro-thrombotic state induced by posttranslational modification of fibrinogen by reactive nitrogen species. J. Biol. Chem. 279(10), 8820-8826 (2004).
45. Mehdi H. Shishehbor, Ronnier J et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 289(13), 1675-1680 (2003).
46. Hink HU, Santanam N, Dikalov S et al. Peroxidase properties of extracellular superoxide dismutase. Role of uric acid in modulating in vivo activity. Arterioscler. Thromb. Vasc. Biol. 22(9), 1402-1408 (2002).
47. Kondo T, Reaume AG, Huang TT et al. Reduction of CuZn-superoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia. J. Neurosci. 17(11), 4180-4189 (1997).
48. Keller JN, Kindy MS, Holtsberg FW et al. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J. Neurosci. 18(2), 687-697 (1998).
49. Abuja PM. Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett. 446(2-3), 305-308 (1999).
50. Maples KR, Mason RP. Free radical metabolite of uric acid. J. Biol. Chem. 263(4), 1709-1712 (1988).
51. Sevanian A, Davies KJ, Hochstein P. Serum urate as an antioxidant for ascorbic acid. Am. J. Clin. Nutr. 54(6), 1129-1134 (1991).
52. Yu ZF, Bruce-Keller AJ, Goodman Y, Mattson MP. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J. Neurosci. Res. 53(5), 613-625 (1998). • An excellent work showing for the first time the potential benefit of UA administration in experimental models of cerebral ischemia.
53. Romanos E, Planas AM, Amaro S, Chamorro A. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J. Cereb. Blood Flow Metab. 27(1), 14-20 (2007). •• An excellent study showing the additive effects of recombinant tissue plasminogen activator (rt-PA) and UA in a model of thromboembolic ischemia in rats.
54. Amaro S, Soy D, Obach V, Cervera A, Planas AM, Chamorro A. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke. Stroke 38(7), 2173-2175 (2007). •• A Phase II trial showing the safety and antioxidant effect of UA adminstration in acute stroke patients receiving rt-PA within the first 3 h of stroke onset.
55. Patschan D, Patschan S, Gobe GG, Chintala S, Goligorsky MS. Uric acid heralds ischemic tissue injury to mobilize endothelial progenitor cells. J. Am. Soc. Nephrol. 18(5), 1516-1524 (2007).
56. Sobrino T, Hurtado O, Moro MA et al. The increase of circulating endothelial progenitor cells after acute ischemic stroke is associated with good outcome. Stroke 38(10), 2759-2764 (2007).
57. Zare F, Magnusson M, Bergström T et al. Uric acid, a nucleic acid degradation product, down-regulates dsRNA-triggered arthritis. J. Leukoc. Biol. 79(3), 482-488 (2006).
58. Ginsberg MH, Kozin F, O'Malley M, McCarty DJ. Release of platelet constituents by monosodium urate crystals. J. Clin. Invest. 60(5), 999-1007 (1977).
59. Kanellis J, Watanabe S, Li JH et al. Uric acid stimulates MCP-1 production in vascular smooth muscle cells via MAPK and COX-2. Hypertension 41(6), 1287-1293 (2003).
60. Netea MG, Kullberg BJ, Block WL, Netea RT, van der Meer JW. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 89(2), 577-582 (1997).
61. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J. Biol. Chem. 266(13), 8604-8608 (1991).
62. Johnson RJ, Kang DH, Feig D et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41(6), 1183-1190 (2003).
63. Khosla U, Zharikov S, Finch J et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 67(5), 1739-1742 (2005).
64. Mazzali M, Kanellis J, Han L et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am. J. Physiol. Renal Physiol. 282(6), 991-997 (2002).
65. Brand FN, McGee DL, Kannel WB, Stokes J 3rd, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: the Framingham Study. Am. J. Epidemiol. 121(1), 11-18 (1985). • Analysis of data from the Framingham Study about the role of UA as a risk factor for coronary disease.
66. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Serum uric acid and 11.5-year mortality of middleaged women: findings of the Chicago Heart Association Detection Project in Industry. J. Clin. Epidemiol. 42(3), 257-267 (1989).
67. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am. J. Epidemiol. 141(7), 637-644 (1995).
68. Mazza A, Pessina AC, Pavei A, Scarpa R, Tikhonoff V, Casiglia E. Predictors of stroke mortality in elderly people from the general population. Eur. J. Epidemiol. 17(12), 1097-1104 (2001).
69. Bengtsson C, Lapidus L, Stendahl C, Waldenström J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med. Scand. 224(6), 549-555 (1988).
70. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am. Heart J. 114(2), 413-419 (1987).
71. Iribarren C, Sharp DS, Curb JD, Yano K. High uric acid: a metabolic marker of coronary heart disease among alcohol abstainers. J. Clin. Epidemiol. 49(6), 673-678 (1996).
72. Wang JG, Staessen JA, Fagard RH, Birkenhager WH, Gong L, Liu L. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 37(4), 1069-1074 (2001).
73. Verdecchia P, Schillaci G, Reboldi GP, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: the PIUMA Study. Hypertension 36(6), 1072-1078 (2000).
74. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34(1), 144-150 (1999).
75. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with noninsulin-dependent diabetes mellitus. Stroke 29(3), 635-639 (1998).
76. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 34(8), 1951-1956 (2003).
77. Anker SD, Doehner W, Rauchhaus M et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107(15), 1991-1997 (2003).
78. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann. Intern. Med. 131(1), 7-13 (1999). • A new analysis of epidemiological data from the Framingham Study; an excellent discussion trying to explain the discrepancies of epidemiological studies about the link of UA and cardiovascular risk.
79. Reunanen A, Takkunen H, Knekt P, Aromaa A. Hyperuricemia as a risk factor for cardiovascular mortality. Acta. Med. Scand. Suppl. 668, 49-59 (1982).
80. Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk In Communities (ARIC) Study. Ann. Epidemiol. 10(3), 136-143 (2000).
81. Yoo TW, Sung KC, Shin HS et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ. J. 69(8), 928-933 (2005).
82. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 37(6), 1503-1507 (2006).
83. Hozawa A, Folsom AR, Ibrahim H, Javier Nieto F, Rosamond WD, Shahar E. Serum uric acid and risk of ischemic stroke: the ARIC Study. Atherosclerosis 187(2), 401-407 (2006).
84. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 148(1), 131-139 (2000).
85. Iuliano L. The oxidant stress hypothesis of atherogenesis. Lipids 36(Suppl.), S41-S44 (2001).
86. Sakamoto A, Ohnishi ST, Ohnishi T, Ogawa R. Relationship between free radical production and lipid peroxidation during ischemia-reperfusion injury in the rat brain. Brain Res. 554(1-2), 186-192 (1991).
87. White BC, Daya A, DeGracia DJ et al. Fluorescent histochemical localization of lipid peroxidation during brain reperfusion following cardiac arrest. Acta Neuropathol. 86(1), 1-9 (1993).
88. Kidwell CS, Liebeskind DS, Starkman S, Saver JL. Trends in acute ischemic stroke trials through the 20th century. Stroke 32(6), 1349-1359 (2001).
89. Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 1(1), 36-45 (2004).
90. Chamorro A, Planas AM, Soy D, Deulofeu R. Uric acid administration for neuroprotection in patients with acute brain ischemia. Med. Hypotheses 62(2), 173-176 (2004).
91. Hooper DC, Scott GS, Zborek A et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J. 14(5), 691-698 (2000).
92. Scott GS, Cuzzocrea S, Genovese T, Koprowski H, Hooper DC. Uric acid protects against secondary damage after spinal cord injury. Proc. Natl Acad. Sci. USA 102(9), 3483-3488 (2005).
93. Wong KY, MacWalter RS, Fraser HW, Crombie I, Ogston SA, Struthers AD. Urate predicts subsequent cardiac death0 in stroke survivors. Eur. Heart J. 23(10), 788-793 (2002).
94. Karagiannis A, Mikhailidis DP, Tziomalos K et al. Serum uric acid as an independent predictor of early death after acute stroke. Circ. J. 71(7), 1120-1127 (2007).
95. Chamorro A, Planas AM. Yin and yang of uric acid in patients with stroke. Stroke 35(1), E11-E12; author reply E11-E12 (2004).
96. Newman EJ, Rahman FS, Lees KR, Weir CJ, Walters MR. Elevated serum urate concentration independently predicts poor outcome following stroke in patients with diabetes. Diabetes Metab. Res. Rev. 22(1), 79-82 (2006).
97. Chamorro A, Obach V, Cervera A, Revilla M, Deulofeu R, Aponte JH. Prognostic significance of uric acid serum concentration in patients with acute ischaemic stroke. Stroke 33(4), 1048-1052 (2002).
98. Waring WS, Webb DJ, Maxwell RJ. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J. Cardiovasc. Pharmacol. 38(3), 365-371 (2001).
99. Waring WS, Convery AA, Mishra V, Shenkin A, Webb DJ, Maxwell SR. Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin. Sci. 105(4), 425-430 (2003).
100. Waring WS, Adwani SH, Breukels O, Webb DJ, Maxwell SR. Hyperuricaemia does not impair cardiovascular function in healthy adults. Heart 90(2), 155-159 (2004).
101. Waring WS, McKnight JA, Webb DJ, Maxwell SR. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes 55(11), 3127-3132 (2006).
102. Mori T, Asano T, Matsui T et al. Intraluminal increase of superoxide anion following transient focal cerebral ischemia in rats. Brain Res. 816(2), 350-357 (1999).